Published: Monday, June 16, 2025 · 1:45 AM | Updated: Monday, June 16, 2025 · 1:45 AM
📊 355 views
Innovent Biologics (IVBXF, Financial) has commenced the GLORY-OSA Phase 3 clinical trial, dosing its first participant. The trial focuses on mazdutide, a dual receptor agonist targeting glucagon and glucagon-like peptide-1, in Chinese patients suffering from moderate-to-severe obstructive sleep apnea and obesity. This marks the seventh Phase 3 study for mazdutide in China, emphasizing its potential role in treating obesity and related metabolic disorders. The goal is to acquire robust evidence to support clinical applications of this treatment.
MORE IN INSIDE INVESTMENT NEWS
HSBC Share Buyback: Bullish Capital Move Amid Strong Q3 Performance
Published: Tuesday, October 27, 2026 · 12:59 AM
AI Funding Fears Rattle Wall Street: Adjusting for Alpha and Preservation
Published: Saturday, October 24, 2026 · 12:28 PM
